Drug Shortages And Biosimilars - NAPLEX

1. Which legal pathway may allow temporary importation of a foreign-approved drug during a shortage?

   FDA enforcement discretion for importation during a medically necessary shortage. FDA may temporarily waive certain regulations to allow importation of unapproved drugs to address critical shortages.

2. What is extrapolation of indications for a biosimilar?

   Approval for additional reference-product indications without direct clinical trials in each indication. Extrapolation relies on scientific justification from similarity data, reducing the need for redundant clinical studies.

3. Which mitigation strategy prioritizes equitable allocation of scarce medication supply?

   Use institution-wide criteria with stewardship and documented prioritization. Institution-wide criteria ensure fair distribution based on clinical need, guided by ethical and stewardship principles.

4. Which operational action best reduces error risk when a shortage forces a new concentration?

   Standardize to one concentration and update order sets and smart pump libraries. Standardization minimizes confusion and errors by aligning protocols and technology with the available concentration.

5. What is an interchangeable biosimilar?

   A biosimilar expected to produce the same clinical result and allow pharmacy substitution per state law. Interchangeability designation involves additional switching studies to confirm equivalent outcomes, enabling automatic substitution.

6. Which naming element helps distinguish biologics and biosimilars in the United States?

   Nonproprietary name with a 4-letter, FDA-designated suffix (e.g., -abcd). The suffix enhances pharmacovigilance by enabling precise identification and tracking of specific biologic products.

7. Identify the best immediate pharmacy response when a critical medication shortage is announced.

   Verify inventory and usage rate, then implement conservation and alternative therapy plan. Assessing current stock and usage enables proactive planning to extend supply and minimize disruptions in care.

8. What does FDA require to approve a biosimilar regarding safety, purity, and potency?

   No clinically meaningful differences from the reference product. FDA approval requires extensive analytical, animal, and clinical data showing equivalence in key quality attributes.

9. Which FDA designation allows pharmacy-level substitution of a biosimilar without prescriber authorization (if state law permits)?

   Interchangeable. This designation requires evidence of safe switching, allowing pharmacists to substitute without prescriber involvement under state laws.

10. What is the primary patient safety risk during a drug shortage?

    Medication errors from substitutions, concentration changes, or unfamiliar products. Shortages necessitate changes in medication use, increasing the likelihood of errors in dosing or administration.

11. What is the key clinical concept distinguishing biosimilars from generic small-molecule drugs?

    Biologics are not identical; biosimilars are highly similar, not exact copies. Biological products are complex and variable, so biosimilars must prove high similarity rather than exact replication.

12. Which FDA center primarily manages shortages for prescription drugs and biologics?

    CDER (Center for Drug Evaluation and Research). CDER oversees the approval and post-market surveillance of most therapeutic drugs, making it central to managing their shortages.

13. What is the most appropriate action when a gray-market vendor offers scarce drugs at high prices?

    Avoid purchase if possible; verify pedigree and report suspicious activity per policy. Gray-market sources pose risks of counterfeit or substandard drugs, necessitating caution and regulatory compliance.

14. What is a biosimilar?

    A biologic highly similar to a reference product with no clinically meaningful differences. Biosimilars demonstrate comparable structure, function, and clinical performance to the originator biologic.

15. Identify the best practice for pharmacovigilance when dispensing a biosimilar.

    Document product and manufacturer (brand name and suffix) to support traceability. Detailed documentation facilitates adverse event reporting and traceability to the exact product in post-marketing surveillance.

16. What is the best first check to confirm whether a "shortage" is local or national?

    Check FDA shortage list and wholesaler availability for the specific NDC. Consulting official sources distinguishes between localized issues and widespread national shortages affecting availability.

17. Which information source is the standard U.S. reference for current drug shortages?

    FDA Drug Shortages database. The FDA database provides official, up-to-date information on national shortages, serving as the authoritative source for healthcare professionals.

18. What is a key supply-chain vulnerability that increases shortage risk for generic injectables?

    Limited manufacturers and single-source API or component suppliers. Generic injectables rely on few producers, making the supply chain susceptible to disruptions from any single point of failure.

19. What is the ASHP definition of a drug shortage?

    Supply issue that affects pharmacy preparation or patient care when alternatives are needed. ASHP emphasizes practical impacts on pharmacy operations and patient care, differing from FDA's supply-demand focus.

20. Which FDA center primarily manages shortages for biologics such as vaccines and blood products?

    CBER (Center for Biologics Evaluation and Research). CBER specializes in regulating complex biological products, ensuring targeted oversight for shortages in vaccines and related items.

21. Which statement best describes formulary management of biosimilars during a shortage of the reference biologic?

    Use therapeutic interchange policy and ensure consistent product selection to reduce switching errors. Formulary policies promote safe substitution of biosimilars, ensuring supply stability and reducing risks from frequent changes.

22. What is the primary regulatory requirement for manufacturers regarding certain shortages?

    Notify FDA in advance of discontinuance or interruption for medically necessary drugs. Advance notification allows FDA to mitigate impacts by identifying alternatives or expediting approvals.

23. Under which U.S. statute are most biosimilars approved?

    Public Health Service Act (PHS Act) via the BPCIA pathway. The BPCIA amends the PHS Act to provide an abbreviated licensure pathway for biosimilars based on similarity to reference products.

24. Identify the most common broad cause category for sterile injectable drug shortages.

    Manufacturing and quality problems (e.g., GMP failures, remediation). Sterile injectables often face shortages due to stringent manufacturing standards and frequent quality control issues.

25. What is the FDA definition of a drug shortage?

    A supply issue that affects how a drug is prepared, dispensed, or used. This captures the FDA's focus on disruptions impacting drug availability and healthcare delivery processes.

Study these flashcards